EGFR Codon 861 Missense
Associated Genetic Biomarkers
EGFR Codon 861 Missense is present in 0.15% of AACR GENIE cases, with lung adenocarcinoma, conventional glioblastoma multiforme, anaplastic astrocytoma, colon adenocarcinoma, and small cell lung carcinoma having the greatest prevalence .
EGFR Codon 861 Missense serves as an inclusion eligibility criterion in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial that contains EGFR Codon 861 Missense as an inclusion criterion, 1 is phase 1 (0 open).
Significance of EGFR Codon 861 Missense in Diseases
Non-Small Cell Lung Carcinoma +
EGFR is altered in 22.89% of non-small cell lung carcinoma patients with EGFR Codon 861 Missense present in 0.72% of all non-small cell lung carcinoma patients .
EGFR Codon 861 Missense is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains EGFR Codon 861 Missense and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.